Development and clinical application of molecular diagnosis in leukemias

白血病分子诊断技术的发展及临床应用

• 批准号: 04557133
• 负责人: HIRAI Hisamaru
• 金额: $ 9.73万
• 依托单位: University of Tokyo
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for Developmental Scientific Research (B)
• 财政年份: 1992
• 资助国家: 日本
• 起止时间: 1992 至 1994
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-04557133/
• 关键词: chromosomal translocation; AML1; EVI-1; chimeric protein; transcription factor; suppressor oncogene; p16 gene; ALL; EVi-1; 癌抑制遺伝子; 転座型白血病; 慢性骨髄性白血病; 急性転化; t(3;21)転座; AML1; EVI-1キメラ遺伝子; 転写因子; 急性前骨髄球性白血病; PML; RARのキメラ遺伝子; t(15;17)転座; RT

The t (3 ; 21) (q26 ; q22)translocation, which is one of consistent chromosomal abnormalities found in blastic crisis of chronic myelocytic leukemia(CML) , is thought to play an important role in leukemic progression of CML to an acute blastic crisis phase. The AML1 gene, which is located at the translocation breakpoint of the t (8 ; 21) (q22 ; q22) translocation found in acute myelocytic leukemia, was also rearranged by the t (3 ; 21) (q26 ; q22) translocation. Screening of a cDNA library of the t (3 ; 21) -carrying leukemic cell line cells (SKH1) resulted in the isolation of AML1/EVI-1 chimeric cDNAs. SKH1 cells expressed the 180 kD AML1/EVI-1 fusion protein containing an amino-terminal half of AML1 including a runt homology domain which is fused to the entire of zinc finger EVI-1 protein. These findings strogly suggest that the t (3 ; 21) translocation results in the fromation of a new class of a chimeric transcription factor which could contribute to leukemic progression of CML thr … More ough interference with cell growth and differentiation. Biochemical analyzes revealed that AML1/EVI-1 itself does not alter the transactivation level through PEBP2 sites but dominantly suppresses the transactivation by intact AML1, which is assumed to be a stimulator of myeloid cell differentiation. The DNA-binding competition is a putative mechanism of such dominant negative effects of AML1/EVI-1 because it binds to PEBP2 sites in the higher affinity than AML1.Furthermore, AML1/EVI-1 stimulated the c-fos promoter transactivation and raised the AP-1 activity. Experiments, using deletion mutants of AML1/EVI-1, showed that these two functions are mutually independent because the dominant negative effects upon intact AML1 and the stimulation of AP-1 activity are dependent on the runt domain and the zinc finger domain near the C-terminus, respectively. Furthermore we showed that AML1/EVI-1 blocks granulocytic differentiation, otherwise induced by G-CSF,of 32Dc13 myeloid cells. It was also suggested that both AML1-derived and EVI-1-derived portions of the fusion protein play crucial roles for such differentiation block. We conclude that the leukemic cell transformation in t (3 ; 21) leukemias is probably caused by those dual functions of AML1/EVI-1 chimeric protein. Less

t（3 ; 21）（q26 ; q22）易位是慢性粒细胞白血病（CML）急变期常见的染色体异常之一，被认为在CML向急性急变期的进展中起重要作用。AML 1基因位于急性髓细胞白血病中发现的t（8 ; 21）（q22 ; q22）易位的易位断裂点，也被t（3 ; 21）（q26 ; q22）易位重排。筛选携带t（3 ; 21）的白血病细胞系细胞（SKH 1）的cDNA文库导致分离AML 1/EVI-1嵌合cDNA。SKH 1细胞表达180 kD的AML 1/EVI-1融合蛋白，含有AML 1的氨基末端一半，包括与整个锌指EVI-1蛋白融合的runt同源结构域。这些发现有力地表明t（3 ; 21）易位导致一类新的嵌合转录因子的形成，这类转录因子可能有助于CML的白血病进展。 ...更多信息 充分干扰细胞生长和分化。生化分析显示，AML 1/EVI-1本身不改变通过PEBP 2位点的反式激活水平，但主要抑制由完整的AML 1，这被认为是一个刺激剂的髓样细胞分化的反式激活。AML 1/EVI-1与PEBP 2位点的结合亲和力高于AML 1，DNA结合竞争是AML 1/EVI-1显性负效应的可能机制。AML 1/EVI-1还可激活c-fos启动子的反式激活，提高AP-1活性。使用AML 1/EVI-1缺失突变体的实验表明，这两种功能是相互独立的，因为对完整AML 1的显性负效应和AP-1活性的刺激分别依赖于C末端附近的runt结构域和锌指结构域。此外，我们发现，AML 1/EVI-1块粒细胞分化，否则诱导的G-CSF，32 Dc 13髓样细胞。还表明融合蛋白的AML 1衍生部分和EVI-1衍生部分在这种分化阻断中起关键作用。结论：t（3 ; 21）白血病的白血病细胞转化可能是由AML 1/EVI-1嵌合蛋白的双重功能引起的。少

项目成果

平井久丸: "臨床分子生物学" 日本臨床社, 874 (1994)

平井久丸：《临床分子生物学》日本临床出版，874（1994）

Mitani K,Sasaki K,Hayashi Y,Mano H,Yazaki Y,Hirai H.: "Molecular analysis of the t (1 ; 19) (q23 ; p13) translocation observed in adult leukemias." Int.J.Hematol.60. 267-271 (1994)

Mitani K、Sasaki K、Hayashi Y、Mano H、Yazaki Y、Hirai H.：“在成人白血病中观察到的 t (1 ; 19) (q23 ; p13) 易位的分子分析。”

Tanaka T,Mitani K,Kurokawa M,Ogawa S,Tanaka K,Nishida J,Yazaki Y,Shibata Y,Hirai H.: "Dual functions of the AML1/Evi-1 chimeric protein in the mechanism of leukemogenesis in t (3 ; 21) leukemias." Mol.Cell.Biol.(In press).

Tanaka T、Mitani K、Kurokawa M、Okawa S、Tanaka K、Nishida J、Yazaki Y、Shibata Y、Hirai H.：“AML1/Evi-1 嵌合蛋白在 t 白血病发生机制中的双重功能（3；

Sugimoto K: "Mutations of the p53 gene in myelodysplastic syndromes and MDS-derived leukemia." Blood. 81. 3022-3026 (1993)

Sugimoto K：“骨髓增生异常综合征和 MDS 衍生性白血病中的 p53 基因突变。”

Tana Ka T: "Dualfauctions of the AML1/Evi-1 chimericprotein in the mechanism of leukemogenesis in t(3;21)leukemias" Mol.Cell.Biol. (In press).

Tana Ka T：“t(3;21) 白血病白血病发生机制中 AML1/Evi-1 嵌合蛋白的双重作用”Mol.Cell.Biol。